Roche Glycart Ag

Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Sylvia Herter

Christian Klein

Ekkehard Moessner

Peter Bruenker

Pablo Umana

Wolfgang Schaefer

Anne Freimoser-Grundschober

Ralf Hosse

Thomas U Hofer

Tilman Schlothauer

Sabine Imhof-Jung

Michael Molhoj

Oliver Ast

Valeria G Nicolini

Marina Bacac

Claudia Ferrara Koller

Stefan Klostermann

Frank Herting

Christiane Neumann

Inja Waldhauer

Joaquin Arribas

Rocio Vicario

Sandra Grau

Christoph Lampert

Valerla G Nicolini

Anne Freimoser-grundschober

The present invention relates to modified antibodies. In particular, the present invention relates to recombinant monoclonal antibodies having altered ability to induce direct cell death and effector function. In addition, the present invention relates to nucleic acid molecules encoding such antibodies, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the antibodies of the invention, and to methods of using these antibodies in treatment of disease.

Antibody fab and Fc variants

The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the &#x3b1;-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

Mutant interleukin-2 polypeptides

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Bispecific T cell activating antigen binding molecules

The present invention relates to bispecific antibodies comprising a first antigen binding site specific for a death receptor and a second antigen binding site specific for a second antigen, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

DR5&#x2014;FAP bispecific death receptor agonistic antibodies

Growing community of inventors

Regensdorf, Switzerland

Sylvia Herter